WOCKPHARMA2018-07-012018-09-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2018-07-012018-09-30in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2018-07-012018-09-30in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2018-07-012018-09-30in-bse-fin:FourOperatingExpenses02Member WOCKPHARMA2018-07-012018-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-07-012018-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-07-012018-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-07-012018-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares WOCKPHARMA 2018-04-01 2019-03-31 2018-10-17 INR Crores Half yearly Single segment Pharmaceuticals 2018-07-01 2018-09-30 Unaudited Standalone 6345900000.00 83800000.00 6429700000.00 1294900000.00 1104300000.00 320600000.00 1347900000.00 434100000.00 286400000.00 1555700000.00 6343900000.00 85800000.00 0.00 85800000.00 0.00 34800000.00 34800000.00 0.00 51000000.00 0.00 0.00 0.00 0.00 51000000.00 -1400000.00 49600000.00 0.00 0.00 553300000.00 5 0.46 0.45 0.00 0.00 0.46 0.45 Notes To Standalone Resultsttttttttttttttttttt n1The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 10 2018. The results have been subjected to limited review by the Statutory auditors of the Company.tttttttttttt n2During the quarter the Company has allotted 12800 Equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options.tttttttttttttttttt n3Effective April 01 2018 the Company has adopted Ind AS 115 Revenue from Contracts with Customersthat has become mandatorily applicable for reporting periods beginning on or after April 01 2018 replacing the existing revenue recognition standard. In accordance with the first time adoption options available in the said standard the Company has chosen the cumulative effect method and applied retrospectively only to contracts that are not completed as at the date of initial application ie April 01 2018. Accordingly the comparatives have not been restated in line with the provisions of the standard. The adoption of the standard did not have any material impact to the financial statements of the Company for the quarter and six months ended September 30 2018tttttttt ntttttttttt n4The Company is exclusively into Pharmaceutical business Segmentttttt ntttttttttt n5Previous period year figures have been recast re-grouped to conform to the current periods presentation.t 2018-04-01 2018-09-30 Unaudited Standalone 11739500000.00 167100000.00 11906600000.00 2433200000.00 2392600000.00 114100000.00 2714700000.00 813300000.00 561200000.00 2960500000.00 11989600000.00 -83000000.00 0.00 -83000000.00 0.00 17100000.00 17100000.00 0.00 -100100000.00 0.00 0.00 0.00 0.00 -100100000.00 1400000.00 -98700000.00 0.00 0.00 553300000.00 5 -0.91 -0.91 0.00 0.00 -0.91 -0.91 Exchange fluctutation loss/(gain) net -231600000.00 Other Expenses 1787300000.00 Exchange fluctutation loss/(gain) net -396200000.00 Other Expenses 3356700000.00 0.00 0.00 0.00